MwanzoBCRX • NASDAQ
add
BioCryst Pharmaceuticals Inc
Bei iliyotangulia
$ 8.38
Bei za siku
$ 8.15 - $ 8.54
Bei za mwaka
$ 6.00 - $ 11.31
Thamani ya kampuni katika soko
2.06B USD
Wastani wa hisa zilizouzwa
4.53M
Uwiano wa bei na mapato
6.81
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 406.56M | 209.09% |
Matumizi ya uendeshaji wa biashara | 93.74M | 16.53% |
Mapato halisi | 245.84M | 1,017.50% |
Kiwango cha faida halisi | 60.47 | 396.86% |
Mapato kwa kila hisa | — | — |
EBITDA | 267.55M | 11,033.92% |
Asilimia ya kodi ya mapato | 0.88% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 274.75M | -14.37% |
Jumla ya mali | 514.16M | 4.84% |
Jumla ya dhima | 633.31M | -34.46% |
Jumla ya hisa | -119.15M | — |
hisa zilizosalia | 250.80M | — |
Uwiano wa bei na thamani | -14.96 | — |
Faida inayotokana na mali | 138.82% | — |
Faida inayotokana mtaji | 204.09% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 245.84M | 1,017.50% |
Pesa kutokana na shughuli | 291.96M | 5,700.61% |
Pesa kutokana na uwekezaji | -83.49M | -569.11% |
Pesa kutokana na ufadhili | -217.96M | -5,320.54% |
Mabadiliko halisi ya pesa taslimu | 5.28M | -27.26% |
Mtiririko huru wa pesa | 200.12M | 2,602.96% |
Kuhusu
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1986
Makao Makuu
Tovuti
Wafanyakazi
435
